For an e-mail response to your Regeneron investment question, please contact us at invest@regeneron.com.

Regeneron is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has candidates in preclinical programs for other diseases and disorders.

More about Regeneron Pharmaceuticals >>

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration - 08/19/08

Study patients, on average, received only two additional doses following a 12-week fixed dosing period Tarrytown, NY and Leverkusen, Germany (August 19, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announc... Full Article >>

Key Clinical Studies of Regeneron's ARCALYST® (rilonacept) for Treatment of CAPS Published  - 08/11/08

Studies highlight rational approach to clinical development for rare, inherited diseases   Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the re... Full Article >>

Regeneron Announces Presentation at the 28th Annual Canaccord Adams Global Growth Conference - 08/08/08

TARRYTOWN, N.Y., Aug 08, 2008 (BUSINESS WIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 28th Annual Canaccord Adams Global Growth Conference on Tuesday, August 12, 2008. The presentation will provide an... Full Article >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.